Foto del docente

Andrea Ardizzoni

Professore ordinario

Dipartimento di Scienze Mediche e Chirurgiche

Settore scientifico disciplinare: MED/06 ONCOLOGIA MEDICA

Direttore Scuola di Specializzazione Oncologia Medica (DI 68/2015)

Pubblicazioni

Tarricone R.; Listorti E.; Tozzi V.; Torbica A.; Banks H.; Ghislandi S.; Altini M.; Annicchiarico M.; Ardizzoni A.; Bordon P.; Bossi P.; Cascinu S.; Numico G.; Puglisi F.; Fasola G., Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy, «JOURNAL OF CANCER POLICY», 2021, 29, Article number: 100297, pp. 1 - 5 [articolo]Open Access

Taronna G.; Leonetti A.; Gustavo Dall'Olio F.; Rizzo A.; Parisi C.; Buti S.; Bordi P.; Brocchi S.; Golfieri R.; Ardizzoni A.; Sverzellati N.; Tiseo M., Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib, «TUMORI», 2021, 00(0), pp. 1 - 8 [articolo]

Mollica V.; Brocchi S.; Dall'olio F.G.; Marcolin L.; Paccapelo A.; Santoni M.; Rizzo A.; Montironi R.; Golfieri R.; Massari F.; Ardizzoni A., Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough, «CANCERS», 2021, 13, Article number: 3492, pp. 1 - 10 [articolo]Open Access

Morgensztern D.; Dols M.C.; Ponce Aix S.; Postmus P.E.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Talbot D.; Govindan R.; Ong T.J., nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+), «FRONTIERS IN ONCOLOGY», 2021, 10, Article number: 569715, pp. 1 - 9 [articolo]Open Access

Massucci, Maria; Di Fabio, Francesca; Rojas Llimpe, Fabiola L; Ardizzoni, Andrea, A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease in Steroid Therapy, «JOURNAL OF IMMUNOTHERAPY», 2020, 43, pp. 153 - 155 [articolo]

Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F., Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2020, 20, pp. 1047 - 1059 [articolo]

Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A., Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [articolo]Open Access

Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A., Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2020, 156, Article number: 103119, pp. 1 - 18 [articolo]

Dall'Olio F.G.; Abbati F.; Facchinetti F.; Massucci M.; Melotti B.; Squadrilli A.; Buti S.; Formica F.; Tiseo M.; Ardizzoni A., CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, Article number: 1758835920952994, pp. 1 - 4 [articolo]Open Access

Felip E.; Ardizzoni A.; Ciuleanu T.; Cobo M.; Laktionov K.; Szilasi M.; Califano R.; Carcereny E.; Griffiths R.; Paz-Ares L.; Duchnowska R.; Garcia M.A.; Isla D.; Jassem J.; Appel W.; Milanowski J.; Van Meerbeeck J.P.; Wolf J.; Li A.; Acevedo A.; Popat S., CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations, «EUROPEAN JOURNAL OF CANCER», 2020, 127, pp. 160 - 172 [articolo]Open Access

Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A., Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience, «LUNG CANCER», 2020, 149, pp. 5 - 9 [articolo]

Giunchi, Francesca; Massari, Francesco; Altimari, Annalisa; Gruppioni, Elisa; Nobili, Elisabetta; Fiorentino, Michelangelo; Ardizzoni, Andrea, Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers, «DIAGNOSTICS», 2020, 10, Article number: 1109, pp. 1 - 5 [articolo]Open Access

Dall'Olio F.G.; Maggio I.; Massucci M.; Mollica V.; Fragomeno B.; Ardizzoni A., ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data, «LUNG CANCER», 2020, 145, pp. 95 - 104 [articolo]

Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A., Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2020, 8, pp. 1 - 3 [articolo]Open Access

Brandes A.A.; Ardizzoni A.; Artioli F.; Cappuzzo F.; Cavanna L.; Frassineti G.L.; Frassoldati A.; Leonardi F.; Longo G.; Maestri A.; Tassinari D.; Franceschi E.; Nunno V.D.; Pinto C., Fighting cancer in coronavirus disease era: Organization of work in medical oncology departments in Emilia Romagna region of Italy, «FUTURE ONCOLOGY», 2020, 16, pp. 1433 - 1439 [articolo]Open Access